Bellevue Life Sciences Acquisition Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of BLAC.U?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	40,000	0.99%
Hedge Funds	262,700	6.5%
Institutions	802,539	19.9%
General Public	1,245,482	30.8%
Private Companies	1,690,500	41.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 16 shareholders own 69.18% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
32.7%	Bellevue Global Life Sciences Investors, LLC	1,320,500	US$4.0m	-2.55%	no data
9.16%	Bellevue Capital Management, LLC	370,000	US$1.1m	-45.6%	no data
6.5%	Walleye Capital LLC	262,700	US$790.7k	0%	0.01%
4.6%	Cowen Inc,Private Banking and Investment Banking Investments	185,761	US$559.1k	-3.94%	0.03%
4.3%	WR Berkley Corp., Asset Management Arm	173,901	US$523.4k	75%	0.08%
3.23%	Clear Street Llc, Asset Management Arm	130,678	US$393.3k	1,420%	0.02%
3.09%	AQR Capital Management, LLC	124,995	US$376.2k	0%	no data
1.99%	Warberg Asset Management LLC	80,228	US$241.5k	102%	2.44%
1.61%	Quarry LP	64,999	US$195.6k	0%	0.15%
0.52%	Susquehanna International Group, LLP, Asset Management Arm	21,007	US$63.2k	-4.47%	no data
0.49%	David Yoo	20,000	US$60.2k	0%	no data
0.49%	Jin Park	20,000	US$60.2k	0%	no data
0.4%	Palmer Square Capital Management LLC	16,328	US$49.1k	0%	0.06%
0.11%	Geode Capital Management, LLC	4,318	US$13.0k	0.37%	no data
0.0054%	UBS Asset Management AG	219	US$659.3	155%	no data
0.0026%	Tower Research Capital Europe Limited	105	US$316.3	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/17 17:28
End of Day Share Price	2025/02/14 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bellevue Life Sciences Acquisition Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.